Disease · MONDO_0005016

diabetic kidney disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetic kidney disease. Diseases, record MONDO_0005016. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005016

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetic kidney disease; Open Targets
Open Targets ID: MONDO_0005016; Open Targets
Other names: DKD, DMII RENAL UNCNTRLD, DMII RENL NT ST UNCNTRLD, Diabetes with renal manifestations, Diabetes with renal manifestations (disorder), Diabetes-nephrosis syndrome, Diabetes-nephrosis syndrome (disorder), Diabetic Glomerulosclerosis, Diabetic Kidney Diseases, Diabetic Nephropathies, Diabetic renal disease, Diabetic renal disease (disorder), Glomerulosclerosis, Diabetic, Glomerulosclerosis, Nodular, Intracapillary Glomerulosclerosis, Kidney Disease, Diabetic, Kidney Diseases, Diabetic, Kimmelstiel - Wilson disease, Kimmelstiel Wilson Syndrome, Nephropathies, Diabetic, Nephropathy, Diabetic, Nephrotic syndrome due to diabetes mellitus, Nephrotic syndrome in diabetes mellitus, Nephrotic syndrome in diabetes mellitus (disorder), Nodular Glomerulosclerosis, Renal disorder associated with diabetes mellitus, Syndrome, Kimmelstiel-Wilson, diabetic nephropathy; Open Targets
MeSH: D003928; MeSH
NCI Thesaurus: C84417; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 150 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs150

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IRBESARTAN	CHEMBL1513	Small molecule	Approval	DailyMed	12	3	3	Drugs and targets
CAPTOPRIL	CHEMBL1560	Small molecule	Approval	DailyMed	14	1	1	Drugs and targets
CORTICOTROPIN	CHEMBL1201610		Approval	TTD	2	1	1	Drugs and targets
LOSARTAN POTASSIUM	CHEMBL995	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
LOSARTAN	CHEMBL191	Small molecule	Phase 3	ClinicalTrials.gov	14	13	10	Drugs and targets
FINERENONE	CHEMBL2181927	Small molecule	Phase 3	ClinicalTrials.gov and TTD	9	8	8	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 3	ClinicalTrials.gov	8	8	7	Drugs and targets
ATRASENTAN	CHEMBL9194	Small molecule	Phase 3	ClinicalTrials.gov and TTD	7	6	6	Drugs and targets
ENALAPRIL	CHEMBL578	Small molecule	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
CANAGLIFLOZIN	CHEMBL4594217	Small molecule	Phase 3	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets

1 to 10 of 150

See all 150 drugs

Targets156

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACE	Angiotensin-converting enzyme	8	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	8	Type-1 angiotensin II receptor antagonist	Approval	https://conductscience.org/library/genes/185	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	8	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets
NR3C2	Mineralocorticoid receptor	5	Mineralocorticoid receptor antagonist	Phase 3	https://conductscience.org/library/genes/4306	Drugs and targets
CCR2	C-C chemokine receptor type 2	4	C-C chemokine receptor type 2 antagonist; C-C chemokine receptor type 2 inhibitor	Phase 2	https://conductscience.org/library/genes/729230	Drugs and targets
EDNRA	Endothelin receptor, ET-A/ET-B	4	Endothelin receptor ET-A antagonist; Endothelin receptor, ET-A/ET-B antagonist	Phase 3	https://conductscience.org/library/genes/1909	Drugs and targets
VDR	Vitamin D3 receptor	4	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
ADORA2A	Adenosine A2 receptor	3	Adenosine A2 receptor agonist; Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	3	Adenosine A2 receptor agonist; Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/136	Drugs and targets
DPP4	Dipeptidyl peptidase 4	3	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets

1 to 10 of 156

See all 156 targets

Trials154

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02545049	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	Phase 3	7,352	2022-04-15	Diabetic Kidney Disease	FINERENONE	Its record names the disease	ClinicalTrials.gov
NCT02540993	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease	Phase 3	5,734	2021-07-19	Chronic Kidney Disease	FINERENONE	Its record names the disease	ClinicalTrials.gov
NCT01858532	Study Of Diabetic Nephropathy With Atrasentan	Phase 3	5,107	2019-04-24	Diabetic Nephropathy	ATRASENTAN	Its record names the disease	ClinicalTrials.gov
NCT02065791	Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy	Phase 3	4,401	2019-11-20	Diabetes Mellitus, Type 2, Diabetic Nephropathy	CANAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT00555217	VA NEPHRON-D: Diabetes iN Nephropathy Study	Phase 3	1,448	2015-05-29	Kidney Disease, Nephropathy, Type 2 Diabetes	LISINOPRIL ANHYDROUS, LOSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00130208	Effect of Sulodexide in Early Diabetic Nephropathy	Phase 3	1,056	2018-03-23	Diabetic Nephropathy	SULODEXIDE	Its record names the disease	ClinicalTrials.gov
NCT01874431	Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy	Phase 2	823	2021-05-04	Diabetic Nephropathies	FINERENONE	Its record names the disease	ClinicalTrials.gov
NCT04492722	A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease	Phase 2	613	2023-12-26	Chronic Kidney Disease	ATULIFLAPON, DAPAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT04170543	A Phase 2b Diabetic Kidney Disease Study	Phase 2	609	2024-07-10	Diabetic Kidney Disease	DAPAGLIFLOZIN, TOZORAKIMAB	Its record names the disease	ClinicalTrials.gov
NCT00141453	ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial	Phase 3	577	2011-05-10	Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria	OLMESARTAN MEDOXOMIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 154

See all 154 trials

Comparisons in its trials44

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.	350 of 3,686	395 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: All-cause Hospitalization	1,573 of 3,686	1,605 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: deaths from any cause	339 of 3,686	383 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: All-cause Mortality	333 of 3,686	370 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death	108 of 3,686	139 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.	458 of 3,686	519 of 3,666	7,352	NCT02545049	Trial comparisons
Finerenone vs Placebo: serious adverse events	1,158 of 3,683	1,215 of 3,658	7,341	NCT02545049	Trial comparisons
Finerenone vs Placebo: All-cause Mortality	219 of 2,833	244 of 2,841	5,674	NCT02540993	Trial comparisons
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death	504 of 2,833	600 of 2,841	5,674	NCT02540993	Trial comparisons
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, or Hospitalization for Heart Failure	367 of 2,833	420 of 2,841	5,674	NCT02540993	Trial comparisons

1 to 10 of 44

See all 44 comparisons in its trials

Papers from its trials242

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35861630	RESULT	1	PubMed
34449181	RESULT	1	PubMed
33264825	RESULT	1	PubMed
33198491	RESULT	1	PubMed
33107592	RESULT	4	PubMed
31753796	RESULT	1	PubMed
31726864	RESULT	1	PubMed
31665733	RESULT	1	PubMed
31583611	RESULT	2	PubMed
31506292	RESULT	1	PubMed

1 to 10 of 242

See all 242 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005016

GET https://conductscience.org/api/diseases/v1/MONDO_0005016/drugs?page=2

API reference For AI assistants